Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03819192
Other study ID # KG-PEONS
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date February 1, 2019
Est. completion date December 31, 2023

Study information

Verified date April 2023
Source Jena University Hospital
Contact Ekkehard Schleußner, Prof. Dr.
Phone +49 3641
Email gabriele.schack@med.uni-jena.de
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

An EONS occurred in nearly 14-22 % of the preterm infant of pregnant women with PPROM. To this day no risk prediction is established. The main aim of this pilot study is generating primary data with a focus on the vaginal microbiome to set-up a prospective, multi-centre trial investigating the role of the vaginal microbiome for future EONS risk prediction. The planned PEONS pilot trial is subdivided in three Work packages: 1. Recruitment, sample collection and routine clinical diagnostics 2. Microbiome analysis by 16S rRNA 3. Microbiome/ Metagenome analysis by "Nanopore" (proof-of-principle) and will enroll women with a PPROM event hospitalized between 22+0 and 34+0 weeks of gestation and neonates with signs of EONS (Subgroup 1) and without signs of EONS (Subgroup 2).


Recruitment information / eligibility

Status Recruiting
Enrollment 150
Est. completion date December 31, 2023
Est. primary completion date December 31, 2023
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - full age pregnant woman with PPROM and their born preterm infants - hospitalization between 22+0 and 34+0 weeks of gestation - multipara possible Exclusion Criteria: - hospitalization with PPROM before limit of viability are reached - intrauterine fetal death - no study agreement - not able to consent

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
microbiome analysis
From all full age pregnant women with PPROM enrolled in this study vaginal smear samples will be taken at three time points: directly after hospitalization 5-7 days after beginning of antibiotic treatment 24 h before birth The microbiome of the neonates of these women will be analysed out of pharyngeal and rectal swabs and umbilical cord blood taken directly after birth and additionally out of the first Meconium.
Conventional cultures
For every sample taken for microbiome analysis, a conventional culture is taken as control.
CAAP48 measurement
CAAP48 is an identified sepsis marker in adult patients. The samples are taken dependent on clinical monitoring to compare CAAP48 with established inflammation markers (CRP, IL-6, White blood cell count, Procalcitonin).

Locations

Country Name City State
Germany University Hospital Halle/s. Halle (Saale) Saxony-Anhalt
Germany Jena University Hospital Jena Thuringe

Sponsors (3)

Lead Sponsor Collaborator
Jena University Hospital Center of Fetal Surgery, University Hospital Halle Saale, Section for Neonatology and Pediatric Intensive Care, University Hospital Halle Saale

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Development of EONS Primary outcome is the development of EONS defined as the presence of confirmed or suspected sepsis at =3 days after birth for which prolonged neonatal antibiotic treatment beyond 72 hours. Confirmed sepsis is established by positive blood cultures whilst suspected sepsis is diagnosed in the presence of clinical suspicion of sepsis (lethargy, apnoea, respiratory distress, hypotension (mean arterial blood pressure (MAD) < gestational age), hypoperfusion and shock) supported by elevated neonatal C-reactive protein (CRP), interleukin-6 (IL6) or blood film suggestive of bacteraemia. 3 days after delivery
Secondary vaginal CST in PPROM the specific patterns of vaginal CST and vaginal microbiota composition (microbiome) in PPROM until delivery
Secondary neonatal microbial colonisation neonatal microbial colonisation (microbiome) on 1st and 2nd day of life up to 2 days after delivery
See also
  Status Clinical Trial Phase
Recruiting NCT06076200 - Population Pharmacokinetic of Piperacillin/Tazobactam in Maternal and Neonatal Populations
Completed NCT03694613 - Utility of Placental/Umbilical Cord Blood in Early Onset Neonatal Sepsis in Very Low Birth Weight Infants N/A
Recruiting NCT03997266 - NICU Antibiotics and Outcomes Trial Phase 4
Recruiting NCT05329701 - Individualized Duration of Antibiotic Treatment in Early Onset Infection in Newborns. Phase 4
Not yet recruiting NCT06377397 - Selective Antibiotics When Symptoms Develop Versus Universal Antibiotics for Preterm Neonates Phase 3
Recruiting NCT06197269 - Efficacy And Safety Of Short Course Antibiotic Therapy In Preterm Neonates With Early Onset Sepsis N/A
Not yet recruiting NCT06100614 - Presepsin to Safely Reduce Antibiotics in Preterm Infants N/A
Not yet recruiting NCT05796115 - PROcalcitonin and Presepsin-guided Decision for Antibiotic Prophylaxis of EOS N/A